Ono Pharmaceutical adopts Kinaxis to enhance global supply chain

Ono Pharmaceutical Co., Ltd. has partnered with Kinaxis Inc., a leading global provider of supply chain solutions, to enhance transparency and visibility across its global operations. The move marks a significant step for the Japan-based pharmaceutical company as it seeks to streamline its supply chain in preparation for increased direct sales in the United States and Europe.

Ono Pharmaceutical, headquartered in Osaka, Japan, is renowned for its focus on research and development, particularly in areas such as oncology, immunology, and neurology. The company’s commitment to creating innovative medicines to address critical medical needs has led to its rapid expansion both domestically and internationally. As part of its growth strategy, Ono is now working to improve the efficiency and agility of its supply chain to meet the demands of an increasingly complex pharmaceutical landscape.

Enhancing supply chain orchestration
To achieve this, Ono has adopted Kinaxis Maestro™, an AI-powered supply chain platform designed to enhance operational efficiencies and provide full visibility across global networks. Kinaxis Maestro™ will allow the pharmaceutical company to respond more swiftly to supply chain disruptions and ensure the stable delivery of its life-saving drugs to patients around the world.

Akira Takada, Corporate Executive Officer and Executive Director of CMC & Production at Ono Pharmaceutical, highlighted the importance of the collaboration: “Under our corporate philosophy ‘Dedicated to the Fight against Disease and Pain,’ Ono is committed to working toward a sustainable society by developing innovative medicines. Kinaxis will be instrumental in improving the efficiency of our supply chain, ensuring that the wide range of therapeutic drugs we produce reaches patients across the globe.”

The AI-driven platform is expected to play a critical role in Ono’s expansion efforts, as the company looks to increase direct sales in key markets such as the US and Europe. The partnership with Kinaxis reflects the company’s ongoing focus on innovation, both in drug development and operational efficiency.

Empowering resilience in uncertain times
Toshiya Kaneko, President of Kinaxis Japan, said: “In today’s uncertain world, the need for agility-driven transformation is more important than ever. With Kinaxis, Ono Pharmaceutical will be able to plan for any scenario, making them more resilient to supply chain challenges. This partnership will support Ono’s mission of delivering life-saving drugs to patients in need.”

The addition of Ono Pharmaceutical to Kinaxis’ client roster further cements the platform’s presence in the life sciences industry. Kinaxis, which supports some of the world’s top pharmaceutical companies, including Dr. Reddy’s, Merck, and Novartis, has become a key player in managing supply chain complexities in the biotechnology, medical devices, and over-the-counter medicine sectors.

Kinaxis’ AI-infused platform provides supply chain solutions that help companies navigate the increasingly complicated pharmaceutical landscape, reducing risks, and enabling faster responses to supply chain disruptions. With Ono Pharmaceutical now on board, Kinaxis continues to expand its footprint within the pharmaceutical sector, ensuring that its clients can meet the growing demands of patients and healthcare providers worldwide.

For further details on how Kinaxis supports supply chain management in the life sciences industry, visit Kinaxis.com.